XFOR — X4 Pharmaceuticals, Inc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1501697 ·
Last close
$3.09
Market Cap
$315.53M
52W High
$4.83
52W Low
$2.43
ADV30
715,995
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,879,000 | 2,366,000 | -19,991,000 | -20,198,000 | 231,816,000 | 185,801,000 | 92,933,000 |
| Jun 2026 | 8,806,000 | 7,189,000 | -16,391,000 | -16,157,000 | 253,063,000 | 195,095,000 | 97,609,000 |
| Mar 2026 | 2,708,000 | 2,110,000 | -20,306,000 | -20,241,000 | 270,281,000 | 216,908,000 | 101,831,000 |
| Dec 2025 | 2,568,000 | 2,204,000 | -23,699,000 | -23,925,000 | 290,461,000 | 217,049,000 | 104,171,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-76,100,000
Investing CF
$46,101,000
Financing CF
$146,057,000
CapEx
$-3,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-651,150,000
Inventory
$5,507,000
Receivables
$1,470,000
ST Investments
$1,900,000
EBIT TTM
$-71,838,000
Pretax Income TTM
$-80,516,000
Interest Exp TTM
$8,678,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$16,961,000
EBITDA
$-71,378,000
Free Cash Flow
$-49,505,752
Enterprise Value
$214,216,096
Total Cash
$187,700,992
Total Debt
$77,196,000
Shares Out
102,113,554
Trailing EPS
$0.55
Book Value
$1.38
ROE
-80.3%
ROA
-23.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,113,000 | -86,883,000 | -79,199,000 | 290,461,000 | 104,171,000 | 186,290,000 | -85,618,000 |
| Dec 2024 | 2,557,000 | -141,401,000 | -37,450,000 | 146,447,000 | 124,298,000 | 22,149,000 | -130,901,000 |
| Dec 2023 | 0 | -107,522,000 | -101,167,000 | 147,258,000 | 96,159,000 | 51,099,000 | -96,512,000 |
| Dec 2022 | 0 | -88,078,000 | -93,867,000 | 155,586,000 | 81,535,000 | 74,051,000 | -77,102,000 |
TTM Snapshot
Revenues TTM
$15,847,000
NetIncome TTM
$-90,138,000
OpCashFlow TTM
—
Assets (Latest)
$253,063,000
Forward EPS
$-0.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | $332.23M | $2.53 | — |
| SCTX | Scribe Therapeutics, Inc. | $298.64M | $15.77 | — |
| KYTX | Kyverna Therapeutics, Inc. | $297.14M | $4.70 | — |
| AGMB | AgomAb Therapeutics NV | $291.55M | $5.92 | — |
| AUTL | Autolus Therapeutics plc | $290.12M | $1.09 | — |
News headlines (Yahoo Finance, 1h cache)
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
2026-11-04 21:50 · Yahoo
X4 Pharmaceuticals: Q3 Earnings Snapshot
2026-11-04 21:31 · Yahoo
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 21:15 · Yahoo
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
2026-11-03 21:30 · Yahoo
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
2026-10-29 20:30 · Yahoo
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
2026-10-29 20:14 · Yahoo
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
2026-10-09 11:00 · Yahoo
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
2026-10-08 12:30 · Yahoo
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
2026-10-08 11:00 · Yahoo
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.